Login to Your Account

Beware the 'Simple' Path: Combo Drug/Devices Tricky

By Marie Powers
Staff Writer

Friday, April 12, 2013
Pity the poor drug developer that thinks using the combination drug/device regulatory pathway through the FDA's Office of Combination Products (OCP) could be a shortcut to approval, bypassing the sometimes unpredictable regulatory oversight of the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription